Earnings Summary

Net Profits


Net Profits:

INOZYME PHARMA INC’s net profit fell -55.66% since last year same period to $-7.74Mn in the Q1 2020. On a quarterly growth basis, INOZYME PHARMA INC has generated -18.25% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the INOZYME PHARMA INC post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

INOZYME PHARMA INC’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a -6.98% fall from last quarter’s estimates.

EPS Estimate Current Year:

INOZYME PHARMA INC’s earning per share (EPS) estimates for the current year stand at -0.46.

Key Ratios

Key ratios of the INOZYME PHARMA INC post its Q3 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)


Earning Per Share (EPS):

INOZYME PHARMA INC’s earning per share (EPS) jumped 36.67% since last year same period to -0.38 in the Q3 2022. This indicates that the INOZYME PHARMA INC has generated 36.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. INOZYME PHARMA INC’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. INOZYME PHARMA INC’s return on equity (ROE) stands at -0.52.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through our in-depth understanding of the biological pathways involved in mineralization, company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. Inozyme is initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

321 Summer Street, Boston, MA, United States, 02210
Health Technology

Trading and brokerage services provided by

Alpaca iconDrivewealth icon

Banking and Remittance services provided by

SBM icon

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*